Mettler-Toledo International (MTD) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
6 Feb, 2026Executive summary
Achieved strong Q4 and full-year 2025 results with broad-based growth across geographies and product categories, demonstrating resilience amid global trade disputes and soft market conditions.
Adjusted EPS grew 8% in Q4 2025 to $13.36 and 4% for the year to $42.73, with excellent free cash flow conversion.
Strategic focus on innovation, automation, digitalization, and onshoring positions the business for continued growth.
Financial highlights
Q4 2025 sales reached $1.13 billion, up 8% year-over-year; local currency sales up 5%.
Adjusted operating profit for Q4 was $363 million (+3% YoY); adjusted operating margin was 32.1%, down 160 bps.
Full-year 2025 sales were $4.03 billion, up 4%; adjusted operating profit declined 1%; adjusted EPS up 4%.
Gross margin for Q4 was 59.8%, down 140 bps; full-year gross margin was 59.4%, down 70 bps.
Free cash flow for 2025 was $878 million; adjusted free cash flow conversion was 99% of adjusted net income.
Outlook and guidance
2026 local currency sales growth forecast at ~4%; adjusted EPS expected at $46.05–$46.70 (+8–9%).
Q1 2026 local currency sales to grow ~3%; adjusted EPS $8.60–$8.75 (+5–7%).
Free cash flow for 2026 projected at ~$900 million; share repurchases of $825–$875 million.
Guidance assumes tariffs remain at current levels and no significant improvement in market conditions.
Management expresses confidence in strategic initiatives and product innovation.
Latest events from Mettler-Toledo International
- Annual meeting covers director elections, auditor ratification, and performance-based executive pay.MTD
Proxy Filing18 Mar 2026 - Director elections, auditor ratification, and say-on-pay vote set for May 7, 2026.MTD
Proxy Filing18 Mar 2026 - Q2 sales fell 4%, but margin gains and service growth led to raised full-year guidance.MTD
Q2 20242 Feb 2026 - Q3 adjusted EPS up 4% on 1% sales growth; Laboratory and Service led gains amid soft markets.MTD
Q3 202415 Jan 2026 - Manufacturing flexibility, innovation, and operational programs drive growth and margin expansion.MTD
Stifel 2024 Healthcare Conference13 Jan 2026 - Innovation, digitalization, and margin expansion fuel global growth and shareholder value.MTD
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Lab and service growth offset China industrial softness; cautious 2025 outlook with service focus.MTD
7th Annual Evercore ISI HealthCONx Conference11 Jan 2026 - Innovation, digitalization, and service drive growth, with margin expansion and 2025 recovery expected.MTD
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Q4 2024 saw double-digit sales and EPS growth, with 2025 guidance reflecting ongoing headwinds.MTD
Q4 20248 Jan 2026